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Abstract
Mounting evidence suggests that transcription factors of the HOX family, previously
best known for their role in embryogenesis, are involved in several other processes, among
them hematopoiesis, and that overexpression can contribute to malignant transformation.
Inhibition of HOX functions may be a potential treatment approach for hematopoietic ma-
lignancies.
In this study we have investigated the effect of HXR9, a peptide designed to inhibit
the interaction between HOX proteins and a cofactor, on acute myeloid leukemia (AML)
cell lines in vitro. We show that AML-cells enter apoptosis when exposed to HXR9, in
addition, the effect is dose-dependent but not specific to HXR9 as the negative control
peptide CXR9 is also cytotoxic to the AML-cells, albeit to a lesser extent. Furthermore, we
show that long time exposure to HXR9 may induce maturation in AML cells, though our
results are inconclusive. Finally, we demonstrate that the cytotoxic efficacy and possibly
pro-maturating effect is independent of the level of HOXA9 — a HOX protein commonly
overexpressed in AML.
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1 BACKGROUND
1 Background
1.1 Hematopoiesis
Hematopoiesis is the formation of blood cells and takes place in the bone marrow. All blood
cells derive from hematopoietic stem cells (HSC) [1]. Expansion of the highly proliferative HSC
and differentiation via different pathways give rise to erythorcytes, thrombocytes and leukocytes
(see figure 1.1).
Figure 1.1: Hematopoiesis. Adapted from [1].
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1.2 Acute Myeloid Leukemia (AML)
Cancer originating from the blood-forming organs is called leukemia. Depending on which
cell line is affected, leukemia can be either lymphatic or myeloid. It can be further classified
as acute or chronic, depending on the rate of progression. AML originates from transformed
hematopoietic progenitors that have acquired a block in differentiation and leads to the accumu-
lation of dysfunctional immature cells (blasts) of myeloid lineage [2]. The rapid expansion of
myeloblasts in bone marrow and blood inhibits the normal hematopoietic function of the bone
marrow and untreated AML soon leads to death [2].
1.2.1 Epidemiology
AML primarily affects the elderly. The annual incidence of AML in Sweden is 340 and the
median age at diagnosis is 71 years [3]. The overall survival 5 years after diagnosis is 20–30%,
highly dependent on the age of the patient and the genetic profile of the malignant cells [3]. In
younger patients (0–49 years of age) the 5-year survival rate is approximately 60% [3].
1.2.2 Subclasses
Subgroups within the AML population show clinically relevant differences in prognosis and re-
sponse to treatment. As an aid in managing with these differences the disease is categorized in
subgroups defined by the World Health Organization (WHO) [2]. All available information, in-
cluding morphology, immunophenotype and genetics, is used for classification [4]. The system
was revised in 2008 and among the changes was the recognition of AML with mutated NPM1
as a separate entity (see table 1) [4].
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Table 1: The WHO classification of acute myeloid leukemias. Adapted from [4].
Acute myeloid leukemia with recurrent genetic abnormalities
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
APL with t(15;17)(q22;q12); PML-RARA
AML with t(6;9)(p23;q34); DEK-NUP214
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
Provisional entity: AML with mutated NPM1
Provisional entity: AML with mutated CEBPA
Acute myeloid leukemia with myelodysplasia-related changes
Therapy-related myeloid neoplasms
Acute myeloid leukemia, not otherwise specified
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia
Acute erythroid leukemia
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to Down’s syndrome
Blastic plasmacytoid dendritic cell neoplasm
25–30% of all AML is still classified as “AML, not otherwise specified” but this group
continues to shrink as more genetic subgroups are identified [4]. The unspecified cases are
divided in groups roughly corresponding to the old FAB (French-American-British) systems
eight subclasses according to morphology (see table 1)[5].
1.2.3 Treatment
The current curative treatment for AML starts with chemotherapy. The aim of the first cy-
cle, induction chemotherapy, is to achieve complete remission (CR), defined as microscopical
disappearance of cancer cells from blood and bone marrow [2]. Following induction therapy,
consolidation therapy is administered whose aim is to eliminate any remaining leukemic cells
[2]. Approximately 70% of patients achieve CR [3]. Unfortunately many patients relapse,
which significantly explains why the long term survival remains as poor as 20–30% despite the
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high rate of CR [3].
In addition to chemotherapy some patients receive allogenic stem cell transplantation [2].
This treatment is associated with significant mortality and morbidity [2], making the choice of
whether or not to proceed with a transplantation something to carefully consider. The risk of
relapse, the availability of a matching donor and the general condition of the patient are taken
into account [2].
In recent years knowledge of the genetic changes and the mechanisms behind AML has
increased significantly [4], which is an important step towards identification of new and more
specific targets for therapy. However, the prognosis remains grim and there is still need for a
better understanding of the mechanisms behind the disease and how these can be exploited in
order to improve patient outcome.
1.3 HOX genes and their role in leukemia
HOX genes code for a family of transcription factors that are well known for their role in
the developing embryo where they control the head-tail axis and decide segmental identity
[1]. The HOX proteins contain a highly conserved peptide sequence, called the homeodomain,
that allows for DNA binding [1]. HOX genes are highly conserved across species and time
[6], presumably due to their vital role in embryonic developement, where disruption of HOX
expression causes malformation [7].
In humans, the HOX genes are found in clusters (A to D) on four different chromosomes
[8]. The organization into clusters is believed to be the results of gene duplications of a single
cluster of genes [8]. HOX genes from different clusters can be aligned according to homology
of their homeobox regions, forming paralog groups, for example HOXA9, HOXB9, HOXC9
and HOXD9 [6]. The gene coding for HOXA9, which is of particular interest in this study, is
found in cluster A and is of the paralog group 9.
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1.3.1 HOXA9 in hematopoiesis
In addition to their role in developmental biology HOX proteins are also involved in hematopoiesis,
among them HOXA9. HOX proteins seem to have a regulating function on hematopoiesis, con-
trolling the proliferation of hematopoietic stem cells (HSCs). This has been demonstrated both
by the inability of HOXA9 deficient mice to repopulate bone marrow after irradiation due to
reduced proliferation [9] and by the fact that overexpression of HOXA9 induces stem cell ex-
pansion [10].
Many HOX genes are strongly expressed in HSCs and early progenitors, but the expression
is downregulated in more differentiated cells [11], suggesting a role in differentiation as well
as in proliferation. Thorsteinsdottir et al. [10] showed that overexpression of HOXA9 induces
a partial block in B lymphopoiesis as well as enhancing myelopoiesis resulting in an increased
number of mature granulocytes. It has also been shown that switching certain HOX proteins on
or off can change the phenotype of blood cells [12].
1.3.2 HOXA9 in leukemogenesis
HOX proteins are expressed in a higher rate in leukemic cells than in normal hematopoietic
cells, where HOX genes normally are downregulated as the cells differentiate [13]. Evidence
suggests that especially the posterior HOXA genes, among them HOXA9, are important in
leuke
mogenesis [14]. One research group has shown that human HSCs treated to over express
HOXA9 were able to establish permanent cell lines [14], and another group reported that over-
expression of HOXA9 transformed bone marrow cells in mice, resulting in AML after 7 months
[15]. The delay suggests that HOXA9 in itself is not enough to transform the cells, and there is
a need for acquisition of further mutations for leuke
mogenesis to occur [10].
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1.3.3 Cofactors
All HOX proteins contain the same polypeptide structure for DNA binding, called the home-
odomain, and while the homeodomain allows DNA binding it does not explain the unique ef-
fects of different HOX proteins, for example the exactness of malformations caused by muta-
tions in or absence of specific HOX genes [1]. However, in addition to the homeodomain, HOX
proteins contain sequences that are distinctive for each HOX protein and allow binding to pro-
tein partners [1]. Such partners, called cofactors, increase the precision of DNA binding as well
as determine whether the activity at the binding site will cause activation or repression [1, 16].
Pre B-cell leukemia transcription factors (PBX) are examples of HOX cofactors, that contain a
homeodomain, but are not part of the clustered HOX gene family. Several studies have shown
that cofactors are involved in hematopoiesis and that they can enhance the transforming ability
of HOX proteins [14, 17].
1.4 Common mutations in AML and their association with HOXA9 over-
expression
Overexpression of HOX proteins in general and HOXA9 in particular is common in AML, and
this feature has been identified as a contributing factor to malignant transformation. However,
as previously mentioned, AML is a genetically diverse disease and there are many pathways and
mutations that can cause leukemic transformation. In order to study the importance of HOXA9
overexpression it is necessary to identify which subgroups of AML that have a high expression
of HOXA9, and preferably to understand the mechanism behind such an overexpression.
1.4.1 The nucleophosmin (NPM1) mutation in AML
The nucleophosmin (NPM1) gene is mutated in one third of all AML, making it the most com-
mon mutation associated with AML [18]. The mutation is always heterozygous, leaving one
functional NPM1 wild type allele [19], and is strongly associated with a normal karyotype
(normal number, shape and size of chromosomes) [18].
6
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In the 2008 revision of WHO classification of myeloid neoplasms, NPM1 mutated AML was
introduced as a separate entity, albeit as a provisional one [4].The following evidence has been
forwarded to support that NPM1 mutations define a separate entity of AML; NPM1 mutation
excludes other recurrent genetic abnormalities and vice versa [20], AML with mutated NPM1
has a distinctive gene expression signature [21, 22], all NPM1 mutations result in cytoplasmic
dislocalization of the protein [18] implicating this as a critical feature.
Normal function of nucleophosmin (NPM) Nucleophosmin (NPM) is a protein expressed in
all human tissues and it has several important functions, some of which are: controlling the du-
plication of centrosomes during mitosis, regulating the response to stress stimuli by modulating
the stability of oncosuppressor p53, and growth-suppression through stabilization of oncosup-
pressor ARF [19]. NPM also plays a vital role in the assembly of ribosomes, thsu contributing
to cell proliferation and growth by chaperoning ribosomal RNA from the nucleus to the cyto-
plasm [19]. To be able to shuttle between the nucleus and the cytoplasm, NPM includes several
sequences regulating its position in the cell, which are all located close to the C-terminus [19].
Among them is a short aromatic stretch including 2 tryptophans at positions 288 and 290 that
are important for binding to the nucleus [23]. In normal tissue most of the NPM is located in
the nucleoli and only a small part is located in the cytoplasm because the nuclear import signals
are stronger than the export signals [19].
Cytoplasmic nucleophosmin (NPMc+) In a paper from 2005 Falini et al. [18] described a
subgroup of AML patients where NPM is dislocated to the cytoplasm, NPMc+. These authors
sequenced the NPM1 gene and identified 6 different mutations, all in exon 12 [18]. The dislo-
cation of the protein is explained by alterations at the C-terminus of the gene, which disrupts
the aromatic stretch including tryptophans at positions 288 and 290 [18], reducing the nuclear
binding capacity of the protein, while simultaneously introducing another nuclear export signal
(NES) [24, 25]. Together this shifts the balance so that most of the mutated NPM dislocates to
the cytoplasm [25]. The mutated NPM then interferes with wild type NPM protein, binding it
to the cytoplasm as well [25].
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The mechanism by which the mutation causes leukemia is still not clear. However, the
mutation has only been found in AML cells [18, 26], strongly suggesting a causal relation. As
previously mentioned, wild-type NPM acts as a oncosuppressor, which means that mutations
involving NPM1 could be oncogenic both through the reduced expression and function of wild-
type NPM (loss of function) and through the function of the mutated NPM (gain of function).
Association between NPMc+ and overexpression of HOXA9 Analysis of NPM-mutated
AML cells showed a distinct pattern of gene expression [22]. Several HOX genes and cofactors
are up-regulated, among them are HOXA9 and PBX3 [22]. The mechanism by which NPMc+
induces overexpression of these proteins is not known. Nevertheless, HOX genes and HOXA9
in particular have been prpposed to induce leukemia, as described in subsection 1.3.2, and thus
upregulation of HOX genes could be part of the mechanism behind NPMc+ AML.
1.4.2 Mixed lineage leukemia (MLL) and the MLL-gene
The MLL gene was identified while searching for the gene involved in translocations found
to be present in a group of infants with leukemia sharing the same clinical profile and poor
prognosis [27]. The hematopoietic blasts of these patients showed signs of both lymphatic
and myeloid differentiation and while some of the patients were diagnosed with AML, others
were diagnosed with Acute Lymphatic Leukemia (ALL) and some even experienced a lineage
switch during the course of the disease [27]. Thus, the gene was named Mixed lineage leukemia
(MLL).
MLL regulates gene expression The MLL gene codes for a histone methyltransferase, an
enzyme able to methylate histone, allowing DNA to unravel and become available for tran-
scription. Among the genes targeted and regulated by MLL is the HOX family [28].
Studies have shown that after transcription of the MLL gene, the protein is cut in two pieces,
N-terminal MLL-N and C-terminal MLL-C [29]. Although cut into separate parts they associate
in the same complex, the MLL complex, where they have different roles. MLL-N is involved
in the targeting and binding to DNA while the MLL-C contains and associates to structures
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important in regulating the transcription of targeted DNA, including chromatin modification
[27].
MLL translocations cause HOX overexpression MLL translocations fuse the MLL N-terminal
to a partner gene [28, 30]. The fusion protein thus shares the N-terminal part with wild type
MLL, while the MLL C-terminal is switched out. To better understand the function of MLL fu-
sion proteins, studies of the fusion partners have been performed. As of yet, 66 fusion partners
have been identified and one of the common partners is AF9 [31]. Studies of the fusion partners
have showed that they are involved in the control of transcription elongation and that several of
them associate in the same complex[27].
Based on these results, it seems reasonable to assume that the MLL fusion protein would
combine binding to MLL wild type target loci (including HOX genes) with transcription elonga-
tion, resulting in a upregulation of the target genes. It has been confirmed that MLL-rearranged
AML cells express high levels of HOX genes [32], and this upregulation is considered to be
a major mechanism by which MLL fusion proteins cause leukemia [28]. The theory is fur-
ther supported by a study which reported that inhibition of HOXA9 using the peptide HXR9,
described in subsection1.5.1, leads to apoptosis of MLL cells [17].
1.4.3 DNA Methyltranferase 3A (DNMT3A)
DNMT3A is an enzyme catalyzing DNA methylation, a process where a methyl group is added
to a DNA nucleotide. DNA methylation is important in the regulation of gene expression by
inhibition of gene transcription. In a study from 2014, Qu et al. [33] showed that AML cells
expressing a mutated form of DNMT3A exhibit global DNA hypomethylation and statistically
significant hypomethylation of HOX genes, implicating an increased expression of these HOX
genes.
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1.4.4 The Myc oncogene
The Myc protein is a multifunctional protein and an important oncoprotein in human cancer.
Myc acts as a transcription factor that promotes growth and is involved in the clocking of the
cell cycle [34]. In 15–20% of human cancers the Myc gene is deregulated, resulting in overex-
pression of the Myc protein, which then operates as an oncoprotein promoting excessive growth
and transformation to cancer [34]. There is no known association between Myc mutations and
HOXA9 over expression.
1.5 Inhibition of HOX proteins
With evidence lining up to support the hypothesis that HOX proteins play a role in the transfor-
mation of hematopoietic cells, it has become interesting to study the effect of HOX inhibition.
There are many ways to inhibit HOX function, one of which is to target the interaction between
HOX proteins and their cofactors. In a study from 2013 Li et al [17] shows that the cofactor
PBX3 is important for leukemic transformation and that inhibition of the interaction between
PBX3 and its HOX partners promotes apoptosis in AML cells.
1.5.1 The HOX inhibitor HXR9
HXR9 was designed by Morgan et al [35] with the intention of creating a peptide that specifi-
cally blocks the interaction between HOX transcription factors and PBX cofactors. In this study
it will be used to study the importance of the interaction between HOXA9 and PBX3.
HXR9 consists of 18 amino acids and contains a hexapeptide sequence (YPWM) and a
polyarginine sequence (R9), see figure 1.2. The YPWM hexapeptide is present in many HOX
Figure 1.2: Peptide sequences for HXR9 and CXR9. The hexapeptide sequence is in bold and
the substituted amino acid is underlined.
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proteins from group 1–9 and is required for their ability to bind to PBX [16, 36]. The pol-
yarginine sequence of 9 consecutive arginine residues is a cell-penetrating peptide that allows
delivery into mammalian cells without the need for any specific receptors [37].
CXR9 is identical to HXR9 except for a single substituted amino acid (figure 1.2). The
substitution disrupts the hexapeptide at a critical point, so CXR9 should not be able to bind to
PBX [16, 36]. CXR9 still carries the polyarginine sequence, which will allow it to enter the cell
and thus work as a negative control.
Previous studies have shown a cytotoxic effect of HXR9 on several different types of cancer
cells, among them melanoma [35], meningioma [38] prostate cancer [39], and breast cancer
[40]. To date, there is only one published study of HXR9 and AML, and it shows that HXR9
causes apoptosis in AML-cells and that the efficacy is dependent on the level of expression of
HOX-genes [17], in accordance with the proposed mechanism of action.
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The overall aim of this study is to determine the effect of the HOX inhibitor HXR9 on AML
cells with different mutations. More specifically:
• Does HXR9 stimulation of AML cells induce apoptosis?
• Can HXR9 stimulation over a longer period of time induce differentiation in AML cells,
as defined by expression of myeloid markers or a reduced capacity to form colonies?
• Is the effect of HXR9 dependent on HOXA9 expression level?
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3.1 Cell cultures
Four human AML cell lines and one murine liquid culture were used in the experiments. The
human cell lines were cultured in Iscoves medium with 10% heat-inactivated fetal calf serum
(FCS), 1% penicillin and streptomycin, 1% L-glutamine, and 1% Na-pyruvate. For the murine
derived liquid culture a DMEM medium with 20% fetal calf serum, 1% penicillin and strep-
tomycin, 1% L-glutamine, 50 pg/ml mouse SCF (stem cell factor), 10 pg/ml human IL-6, and
6 pg/ml mouse IL-3 was used. Passaging of the cells was performed three times a week. A
description of the cell lines follws:
3.1.1 HL-60
The HL-60 cell line was established from a 36-year old female and carries a mutation in the
Myc gene [41]. In a study by Li et al it was shown that HL-60 has a low expression of HOXA9
and that the cells are not affected by stimulation with HXR9/CXR9 and is therefore used as a
negative control [17].
3.1.2 THP-1
According to the distributor ATCC the THP-1 cell line was established from a 1 year old male
infant [42]. THP-1 cells have the translocation t(9:11) resulting in the MLL-AF9 fusion gene
[43]. MLL fusion proteins are known to induce overexpression of HOX proteins (see subsection
1.4.2) and this particular cell line has been shown to become apoptotic in the presence of HXR9
[17], making it suitable as a positive control in this study.
3.1.3 OCI-AML2
According to the distributor Leibniz-Institut DSMZ the cell line was “established from the
peripheral blood of a 65-year-old man with acute myeloid leukemia (AML FAB M4) in 1986 at
diagnosis”[44]. This cell line carries a DNMT3A mutation but no mutation in NPM1.
13
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3.1.4 OCI-AML3
According to the distributor Leibniz-Institut DSMZ the cell line was: “established from the
peripheral blood of a 57-year-old man with acute myeloid leukemia (AML FABM4) at diagnosis
in 1987” [44] and “cells carry an NPM1 gene mutation (type A) and the DNMT3A R882C
mutation” [44].
3.1.5 HOXA9
This liquid culture was established by Hanna Grauers Wiktorin at Sahlgrenska Cancer Center
using murine bone marrow cells which were transfected with an E86-HOXA9 producing retro-
virus to express human HOXA9. The transfected cells are tagged with green flourescent protein
(GFP).
3.2 Western blot
The Western blot method is used to examine the protein expression of cells. Gel electrophoresis
of cell lysates separates the proteins according to size. From the gel the proteins are blotted
onto a membrane and stained with primary and secondary antibodies. The secondary antibodies
carry horse radish protein (HRP), which produces chemiluminescence when HRP-substrate is
available. The chemiluminescence can be detected by a camera, resulting in a photograph where
only the stained proteins are visible.
3.2.1 Analysis of the expression of HOXA9, NPM wild type and mutated NPM
In this project the cell lines OCI-AML3, OCI-AML2, THP-1, HOXA9 and HL60 were analyzed
for the expression of HOXA9, NPM wild type and NPM mutation A in order to confirm the
characteristics of each cell line.
Approximately 5 million cells of each cell line were harvested, spun down and then re-
suspended in 1 ml of cold phosphate buffered saline (PBS). The samples were transferred to
transparent 2 ml eppendorf tubes and centrifuged again. NuPAGE LDS buffer was prepared as
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follows: 1300 ul RNAse free water was mixed with 500 ul of NuPAGE LDS buffer 4x (Life
Technologies) and 200 ul of dithiothreitol. After centrifugation the supernatant was removed
and the cell pellets were carefully resuspended in 200 ul of the prepared buffer. The samples
were then sonicated for 10 minutes, heated to 75ºC for 5 minutes and finally centrifuged. As
the samples were still not sufficiently denatured they were sonicated again for 10 minutes, after
which they were set for loading on the gel.
NuPAGE 10% Bis-Tris-Gels from Life Technologies were used. Four gels were prepared;
one for HOXA9, one for NPM wild type, one for mutated NPM and one for β -actin, used as
a loading control. To each gel 15 ul of ladder (SeeBlue Plus2 Prestained Standard, Life Tech-
nologies) and 20 ul of each cell line were loaded. The gels were placed in the electrophoresis
chambers (XCell SureLock Mini-Cell, Life Technologies) that had been prepared with MOPS
SDS running buffer (Life Technologies). Electrophoresis was performed according to manufac-
turer’s instruction, after which the gels were transferred to containers with methanol. The gels
were loaded in two blotting machines (TransBlot SD, BioRad) along with Nitrocellulose Blot-
ting Membranes (Life Technologies) and filters soaked in methanol. Blotting was performed
according to manufacture’rs instruction. After blotting the membranes were washed in tap wa-
ter several times. Panceau S dye was applied to the membranes, to confirm that proteins have
been blotted onto the membranes. The membranes were washed in methanol to remove the dye,
followed by TBST (tris buffered saline with tween) to wash away the methanol. They were then
incubated in milk buffer (Blotting Grade Buffer, BioRad) for 1 hour on a rotary shaker. After 1
hour of incubation the membranes were put in individual sealed plastic bags along with a milk
buffer containing one of the primary antibodies. The bags were then fastened to a rocking plate
in a cold room and incubated over night.
The next day the membranes were washed 3 times for 10 minutes in TBST on a rotating
shaker. After washing, the membranes were put in new plastic bags along with a milk buffer
containing the secondary antibody, carrying HRP. The plastic bags were taped onto a rocking
plate and left to incubate for 1 hour in room temperature. After the secondary staining the
membranes were once again washed in TBST, 3 times for 10 minutes, on a rotating shaker.
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For development, Thermo Scientific Pierce Fast Western Blot Kits, SuperSignal West Dura
was applied according to manufacturer’s instructions except for mutated NPM, where Thermo
Scientific Pierce Fast Western Blot Kit, SuperSignal West Femto was used. Pictures were taken
using a ChemiDoc MP System (BioRad).
Table 2: Antibodies used for Western blot
ANTIGEN CLONE MANUFACTURER
β -actin unknown Cell Singaling
HOXA9 Polyclonal Millipore
NPM1 wt EP1848Y Abcam
NPM1 mut A Polyclonal Abcam
Anti-rabbit-HRP Polyclonal Cell Singaling
3.3 The peptides HXR9 and CXR9
The peptides were bought and delivered by Biosynthesis with a guaranteed purity of 85%.
Peptides were dissolved in water and stored as aliquots at -80ºC.
3.4 Alamar Blue assay
The assay was used to examine cell viability by measuring the metabolic activity of cells. Ala-
mar Blue Cell Viability Reagent (Life Technologies) reagent is added at 1:10 to a sample con-
taining cells. The cells metabolize the reagent, causing it to shift color from blue to red. A
plate reader (FLUOstar Omega, BMG Labtech) provides measurement of the absorbance of
two wavelengths and the data are analyzed using an equation provided by the datasheet (see
appendix A.1) to determine how much of the reagent has been metabolized, which corresponds
to the viability/number of cells. For cytotoxicity assays, the procedure is identical, except that
the data are analyzed using another equation (see appendix A.1) to determine the ratio of un-
treated/viable cells compared to a positive growth control.
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3.4.1 Optimization of cell counts and incubation time
In order to get a reading within range and thus be able to detect differences in cell viability for
the cytotoxicity assay, cell counts and incubation time must be optimized. Triplicate samples
consisting of different number of cells dissolved in 100 ul of medium each were planted in
flat-bottomed 6 well plates. The surrounding wells were filled with PBS (phosphate buffered
saline), to protect from evaporation. After seeding the cells were allowed to recover for 20
hours and then another 20 hours (corresponding to the time for peptide stimulation). After 40
hours the Alamar Blue reagent was added and the cell viability was assessed at different time
points, as previously described in subsection 3.4.
3.4.2 Cytotoxicity assay
Samples consisting of 50,000/75,000/100,000 cells (see subsection 5.2) dissolved in 100 ul of
medium each were used and all samples were triplicated (figure 3.1). The samples were seeded
in flat-bottomed 96 well plates with PBS in the surrounding wells. A triplicate of medium blank
samples (without cells) was also added to the plate. After seeding, the cells were allowed to
recover for 20 hours, after which the peptide HXR9 was added resulting in concentrations of
0, 1, 5, 10, 15, 20, 30, 40 uM. CXR9 was used as a negative control and was added at the
same concentrations. After 20 hours of peptide stimulation, the Alamar Blue reagent was added
followed by four hours of incubation (24 hours of peptide stimulation) after which relative cell
viability was assessed, as previously explained in subsection 3.4.
Conc. (uM) 0 1 5 10 15 20 30 40 Blank
HXR9
HXR9
HXR9
CXR9
CXR9
CXR9
Figure 3.1: Plate set-up for peptide stimulation for the Alamar Blue cytotoxicity assay. Each
well except those in the blank column contain 50,000/75,000/100,000 cells dissolved in 100 ul
of medium in addition to the indicated peptide.
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3.5 Flow cytometry
Flow cytometry is a method for sorting or analyzing cells with the aid of antibodies or other
proteins that can bind to cell structures carrying fluorochromes. A fluorochrome is a chemical
compound that emits electromagnetic radiation at a specific wavelength upon absorption of
light.
Flow cytometry data are presented as a dot plot where each dot represents one cell. In
addition to the fluorescence provided by staining, the cells are discriminated by the results of
a forward scatter (FSC) and side scatter (SSC) analysis, which corresponds to the cell size and
structure/granularity, respectively.
3.5.1 Annexin V apoptosis assay
Necrotic Late
Apoptotic
Early
Apoptotic
Live
To
Pr
o/
7A
AD
Annexin
Figure 3.2: Expected distribution of cells in the
annexin V apoptosis assay.
In this assay the Invitrogen Annexin V-FITC
Apoptosis Detection kit is used. It con-
tains Annexin V-FITC, which binds to phos-
phatidylserine exposed on apoptotic cells,
and ToPro which binds to DNA and is used as
a general marker for cell death. Together they
allow discrimintation between live, apoptotic
and necrotic cells (see figure 3.2). As the
HOXA9 cells already carry a GFP-tag (see
subsection 3.1.5) another set of antibodies
was used for this cell line; Annexin V-Cy5.5 (BD Biosciences) and 7AAD (BD Biosciences).
Cy5.5 is just another fluorochrome and 7AAD is a live-dead marker, similar to ToPro, but fluo-
rescent at another wave-length.
For the assay, duplicate samples consisting of 100,000/75,000/50,000 cells (see subsection
5.2) suspended in 100 ul of medium each were seeded in a flat -bottomed 96 well plate, with
PBS in the surrounding wells, and allowed to recover for 20 hours. The peptides HXR9 and
CXR9 were then added to give final concentrations of 10 uM and 20 uM while one sample
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was kept as a negative control (no peptide). After 24 hours of peptide stimulation the paired
samples were pooled and washed twice in PBS. After washing, the cells were dissolved in 100
ul of Annexin V-buffer mixed with 2 ul of Annexin V-FITC and 2 ul of ToPro3 or 1 ul of
7AAD. The samples were then incubated in the dark for 10 minutes at room temperature and
then diluted with 150 ul Annexin V-buffer before being ready for analysis in the flow cytometry
equipment, LSRFortessa (BD Biosciences).
3.5.2 Maturation assay
The aim of this assay was to see if cells cultured in the presence of HXR9 mature, as defined
by the expression of myeloid markers. Two panels were designed, one for human and one for
murine cells, see table 3.
Table 3: Antibodies used for the maturataion assay. For the human panel the human antibodies
and DAPI were used. For the murine panel the murine antibodies were used along with DAPI
and GFP.
ANTIGEN FLUOROCHROME REACTS
WITH
FINAL CONCEN-
TRATION
CLONE MANUFACTURER
CD11b PE Human 1:20 ICRF44 BD Biosciences
CD14 APC-Cy7 Human 1:40 Mφ-P9 BD Biosciences
CD11b APC-Cy7 Mouse 1:400 M1/70 BD Biosciences
Gr1 PE Mouse 1:1000 RB6-8CF BD Biosciences
F4/80 APC Mouse 1:50 MF48021 Invitrogen
I-A/I-E PerCP-Cy5.5 Mouse 1:100 M5/114.15.2 BD Biosciences
(nuclear acid
dye)
DAPI Human,
mouse
1:3 N/A unknown
(cell tag) GFP N/A N/A N/A N/A
Cells were cultured and passaged as usual for seven days with the addition of one of HXR9,
CXR9, DMSO (positive control) or nothing. Cells were seeded in a flat-bottomed 48 well plate
using 1 ml samples at normal passaging concentrations, depending on cell line. The peptides
and DMSO were added at seeding and passaging: The peptide concentration was 10 uM for
HL60, OCI-AML2, OCI-AML3 and HOXA9 and 5 uM for THP-1. The DMSO concentration
was 0.25% for HOXA9, 0.5% for OCI-AML2 and OCI-AML3 and 1% for HL60 and THP-1.
After seven days the cells were analyzed using the flow cytometry equipment, LSRFortessa (BD
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Biosciences), to characterize the expression of myeloid markers.
In preparation for cytometry analysis, the cells were transferred from the plate to tubes
and washed twice in E-buffer (PBS with 2 mM EDTA and 0,5% Bovine Serum Albumine).
Antibody mixtures were prepared for each panel using E-buffer and appropriate concentration
of each antibody. After washing, the cells were transferred to a round-bottomed 96 well plate.
The murine cell samples were suspended in 25 ul of a Fc-block and incubated for 5 minutes
in room temperature. After incubation, both the human and murine cells were suspended in
50 ul of the appropriate antibody mixture and then incubated in at 4ºC for 30 minutes. After
incubation the cells were washed twice and suspended in a 133 ul E-buffer. Immediately prior
to the analysis 67 ul of DAPI 3x was added.
3.6 Colony Forming Units (CFU) assay
Hematopoietic stem cells and precursors have the ability to form colonies when cultured in a
semisolid medium containing growth promoting and pro-differentiating cytokines. Each colony
derives from a single cell, which means that all the cells in a colony are clones. It is possible
to distinguish between different types of colonies, corresponding to the different hematopoietic
progenitors, depending on the appearance of the colonies. Granulocyte colonies (CFU-G) ap-
pear dense and small, with few satellite cells [45]. Macrophage colonies (CFU-M) are sparser
but cover a larger area [45]. The appearance of granulocyte-macrophage colonies (CFU-GM)
is a mixture of CFU-G and CFU-M. [45]
As cells differentiate they tend to lose their ability to proliferate. By measuring the number
of colonies that form in comparison to the number of cells that were plated, the CFU assay
provides a measure of the degree of differentiation of the cells cultured. The number of replat-
ings provides another measure of the cells’ ability to proliferate. As more and more of the cells
differentiate over time, fewer and fewer of them will be able to proliferate, eventually making
replating impossible. Replating can also help selecting the cells that are able to form colonies,
resulting in more colonies after a one or a few replatings. Normally at least four replatings are
performed to assess maturation of cells.
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3.6.1 CFU Assay with HL60 and OCI-AML3
3 ml Methocult
50000/ml
CXR9 HXR9
300 ul
1,1 ml
5000/ml
CXR9 HXR9
3 ml Methocult
300 ul
1,1 ml
Figure 3.3: Lay-out for the plating of CFUs.
The aim of this assay is to see if HXR9 can
make leukemic cells lose their stem cell-like
ability to proliferate, as defined by a reduced
capacity to form colonies. Only OCI-AML3,
carrying the NPM1 mutation, and the nega-
tive control cell line HL60 is included in this
experiment.
A MethoCult H84534 (StemCell Tech-
nologies) semisolid medium was used, con-
taining methylcellulose in Iscoves medium,
fetal bovine serum, bovine serum albumin,
2-mercaptoethanol, recombinant human stem
cell factor, recombinant human GM-CSF, recombinant human G-CSF, and recombinant human
IL-3.Cells were taken from culture and diluted to 500,000 cells/ml in Iscoves’ medium without
any additives. This solution was then diluted 1:10 to 50,000 cells/ml and again 1:10 to 5,000
cells/ml, see figure 3.3. From these two solutions 300 ul was added to a prepared vial of 3 ml
MethoCult H84534 (Stem Cell Technologies), resulting in 5000 cells/ml and 500 cells/ml. 3
vials of Methocult was prepared for each cell line and each cell concentration. HXR9 and CXR9
were added to one of the tubes each, to a final concentration of 10 uM, while one tube was kept
as a negative control. The content of each tube was transferred to two 35 mm petri dishes, 1.1
ml for each dish, using a 5 ml syringe with a blunt needle, resulting in 5 000 cells/plate and 500
cells/plate. The lower concentration was intended for counting and the higher concentration for
replating. The paired petri dishes were placed in a 100 mm petri dish together with an open 35
mm petri dish containing distilled water, to prevent the methocult from drying out.
After 6–8 days of incubation in 37 °C and 5% CO2, colonies were counted on the plates
seeded with 500 cells/plate, with the aid of a microscope and a gridded petri dish.
One day after counting the cells were replated. In order to dissolve the methocult, PBS
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was added and the methocult was scraped from the petri dishes and tranferred to a 50 ml tube.
The procedure was repeated until all methocult had been scraped off. PBS was added to a final
volume of 30 ml and the liquid was mixed using a pipette and then centrifuged.
After centrifugation the supernatant was removed, leaving 1–2 ml of PBS. PBS was then
added to 20 ml volume, mixed and then centrifuged again. The washing was repeated once
more before the cells were counted and then plated, as previously described.
3.7 Statistical analyses and graphs
FlowJo V10 has been used for analysis of flow cytometry data and creation of dot plots. Creation
of graphs and statistical analyses (Student’s t-test) have been performed using GraphPad Prism
6.
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The experiments involving laboratory mice performed during the establishment of the HOXA9
liquid culture were approved by the applicable committee. All other experiments have been
performed in vitro using established cell lines.
23
5 RESULTS
5 Results
5.1 Characterization of protein expression
In initial experiments, the expression of NPM1, mutated NPM1 and HOXA9 was determined.
Results from the Western blot showed that: all cell lines expressed wild-type NPM (see fig-
ure 5.1b), only OCI-AML3 expressed the mutated version of NPM (see figure 5.1c), and THP-
1, OCI-AML2, OCI-AML3 had a high expression of HOXA9 while the HOXA9 liquid cul-
ture showed an even higher expression (see figure 5.1d). HL60 had a very low expression of
HOXA9.
(a) β -actin, loading control. (b) Wild-type nucleophosmin
(c) Nucleophosmin mutation A (d) HOXA9
Figure 5.1: Western blot
24
5.2 Peptide induced cytotoxicity 5 RESULTS
5.2 Peptide induced cytotoxicity
To investigate the effect of HXR9 an Alamar Blue cytotoxicity assay was set up and performed.
Initial test runs showed that with an incubation time of 4 hours, cell counts of 100,000 for
HOXA9, 75,000 for HL60, OCI-AML2 and OCI-AML3 and 50,000 for THP-1 were chosen
when using 100 ul samples (figure A.1). As many samples were needed, samples with a small
volume were desirable.
Data from three independent experiments with triplicate samples showed that all the ex-
amined cell lines expressed a reduced viability after exposure to HXR9, as can be seen in
figure 5.2. The cells also appeared to be sensitive to CXR9, albeit to a lower extent. The ef-
fect of HXR9/CXR9 became significant at 15/40 uM for HL60, 10/15 uM for THP-1, 5/10 uM
for OCI-AML2, 30/20 uM for OCI-AML3, and 40/- for HOXA9. The effect of the CXR9 on
HOXA9 cells may be significant, but more data is needed as the measured variability is too
high.
The specific effect of HXR9 has been calculated as the difference in viability between expo-
sure to HXR9 and CXR9 at a given concentration. The Student’s t-test was performed in order
to determine the significance of this specific effect. For THP-1 and OCI-AML2 the specific
effect was significant at middling concentrations, but at higher concentrations the curves for
CXR9 and HXR9 seem be about to converge (see figure 5.2). For OCI-AML3 the specific ef-
fect became significant at 30 uM and increased at higher concentrations. For HL60 the specific
effect was significant only at 40 uM. For HOXA9 the specific effect was not significant at any
of the concentrations examined, due to a high variability between experiments.
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Figure 5.2: Alamar Blue cytotoxicity assay. Cell viability after 24 hours of HXR9/CXR9 pep-
tide stimulation. Mean values and SEM from three independent experiments are shown. One,
two, or three * symbols denote a significant difference between HXR9 and CXR9 at the indi-
cated concentrations, according to a Student’s t-test with a p-value of <0.05, 0.01, and 0.005,
respectively.
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To further investigate the cytotoxic effect of HXR9 and to determine if the reduced viability
seen in the Alamar Blue cytotoxicity assay (see subsection 5.2) was due to induction of apopto-
sis, a flow cytometry assay using annexin V and a live-dead marker was performed. Cells were
treated with CXR9 and HXR9 for 24 hours followed by flow cytometry to measure the ratio
of apoptotic, necrotic and live cells. Representative dots plots from one of three independent
experiments are shown in figure 5.3.
The data showed that all the cell lines examined die when exposed to HXR9, and to a lesser
extent when exposed to CXR9. The effect of HXR9/CXR9 became significant at 10/10 uM for
HL60, 10/20 uM for THP-1, 10/10 uM for OCI-AML2, 10/20 uM for OCI-AML3 and 10/- uM
for HOXA9. In addition the data showed that cells die from apoptosis rather than necrosis, see
figure 5.4.
For this assay the specific effect of HXR9 has been calculated as the difference in percentage
of apoptotic cells in samples exposed to HXR9 compared to samples exposed to CXR9. Test
of significance with Student’s t-test shows that the specific effect is significant for THP-1 and
OCI-AML2 at 10 uM and for HL60 and HOXA9 at 20 uM (figure 5.5). For OCI-AML3 the
effect is not significant at either 10 or 20 uM.
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Figure 5.3: Annexin V apoptosis assay. Representative dot plots from one of three independent
experiments are shown.
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Figure 5.4: FACS annexin V apoptosis assay, with early (up) and late (down) apoptotic cells
shown in separate graphs. A majority of the apoptotic cells are in the late stage. Less than 3 %
of cells were annexin V-ToPro/7AAD+ (not shown) in all samples. Mean values and SEM from
three separate experiments are shown.
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Figure 5.5: Annexin V apoptosis assay, sum-
mary of all apoptotic cells. Annexin V+ in-
clude both ToPro/7AAD+ and ToPro/7AAD-
cells. One, or two * symbols denote a signif-
icant difference between HXR9 and CXR9
at the indicated concentrations, according
to a student t-test with a p-value of <0.05,
and 0.01 respectively. Mean values and
SEM from three independent experiments
are shown.
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5.3 Peptide induced maturation
To investigate any pro-differentiating effect of HXR9, flow cytometry panels were set up, one
for human and one for murine cells. Two of the human cell lines, HL60 and OCI-AML3, were
also studied using a CFU-assay.
5.3.1 Human cell lines
Results from the flow cytometry panel showed that there is a trend towards increased expres-
sion of CD11b in OCI-AML3 after stimulation with HXR9 and CXR9 (figure 5.6b). HXR9
significantly increases the expression of CD14 in OCI-AML3 and there seems to be a trend
towards increased expression in OCI-AML2 and HL60. The results also showed that THP-1
has a higher percentage of CD11b+ and CD14+ cells than the other cell lines without stimu-
lation and that while DMSO significantly increases expression of CD11b and CD14 in HL60
and CD11b in THP-1, there is no significant increase in expression of either CD11b or CD14 in
OCI-AML2 or OCI-AML3 after stimulation with DMSO. Representative histograms from one
of three independent experiments are shown in figure 5.6a.
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(a) Representative histograms from one of three in-
dependent experiments.
Ne
g
DM
SO
CX
R9
HX
R9 Ne
g
DM
SO
CX
R9
HX
R9 Ne
g
DM
SO
CX
R9
HX
R9 Ne
g
DM
SO
CX
R9
HX
R9
0
20
40
60
80
100
120
%
C
D
11
b
+
HL60
THP-1
OCI-AML2
OCI-AML3
**** **
Ne
g
DM
SO
CX
R9
HX
R9 Ne
g
DM
SO
CX
R9
HX
R9 Ne
g
DM
SO
CX
R9
HX
R9 Ne
g
DM
SO
CX
R9
HX
R9
0
20
40
60
80
100
%
C
D
1
4
+
HL60
THP-1
OCI-AML2
OCI-AML3
***
****
(b) Percentage of cells that are positive for the
myeloid markers CD11b and CD14. One, two, three,
or four * symbols denote a significant difference, ac-
cording to a Student’s t-test with a p-value of <0.05,
0.01, 0.005, and 0.001 respectively. Mean and SEM
from three independent experiments are shown.
Figure 5.6: Maturation assay, human cell lines.
The CFU-assay showed that both HL60 and OCI-AML3 were able to form colonies. The
HL60 colonies had the appearance of CFU-G, being small and dense, whereas the OCI-AML3
colonies were numerous but sparse, with the appearance of CFU-M or CFU-GM. During the
first week HL60 formed less than 50 colonies per plate, but the second week it formed as many
colonies as OCI-AML3 in the untreated sample. For HL60 both CXR9 and HXR9 seemed to
inhibit the formation of colonies, although the effect of CXR9 was weaker (see figure 5.7). For
OCI-AML3 HXR9, but not CXR9, seemed to inhibit the formation of colonies (figure 5.7). No
statistical analysis could be performed as there were too few samples.
The experiment was canceled after the second week as results from the other experiments
indicated that the effect of HXR9 was less specific than previously thought.
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Figure 5.7: CFU assay. Colony count 6 days (8 days for the 1st plating) after plating of 500
cells on a small petri dish. The arithmetic mean from duplicate samples is shown.
5.3.2 Murine cells
Only two replicates of the flow cytometry maturation assay were performed on the HOXA9
liquid culture. Due to methodological difficulties the two experiments were performed nearly
one month apart (2015-03-25 and 2015-04-24). The results showed a decrease in expression
of the markers examined in all samples, regardless of stimulation and the results were deemed
non-comparable, see figure 5.8. Thus, no synthesis graphs are shown.
Figure 5.8: Maturation assay, HOXA9 liquid culture. Histograms from two independent ex-
periments performed one month apart, 2015-03-25 and 2015-04-24, show different patterns of
expression.
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6.1 Gene expression analysis
The Western blot confirmed the expression of wild type NPM in all cell lines and the presence
of mutated NPM exclusively in OCI-AML3, in accordance with the distributor DSMZ[46] and
Quantmeier et al [47]. The HOXA9 expression is high in positive control cell line THP-1, in
accordance with previous studies [17, 28] as well as in OCI-AML2, OCI-AML3, also in accor-
dance with previous reports [33, 22]. The liquid culture HOXA9 has a very high expression of
HOXA9, which is consistent with transfection of the human HOXA9 gene. HL60 show only a
low/moderate expression of HOXA9.
These results confirm that HL60 is suitable as a negative control cell line for this study as it
does not carry a mutation in the NPM1 gene and has a low expression of HOXA9. Furthermore
THP-1 is suitable as a positive control, with no mutation in NPM1 but a high expression of
HOXA9. It is also confirmed that OCI-AML3 carries a mutation in NPM1, and can thus be
used as an in vitro model of NPMc+ AML.
6.2 The cytotoxic effect of HXR9
The Alamar Blue cytotoxic assay showed a reduced viability of AML cells after exposure to
HXR9 in a dose-dependent manner (figure 5.2). However, it is not possible to distinguish if the
reduced viability is due to a reduced proliferation or an actual cytotoxic effect in this assay. The
annexin V apoptosis assay showed that cells exposed to HXR9 die by apoptosis (figure 5.4),
which indicates that HXR9 is cytotoxic to AML cells. According to the Alamar Blue assay,
THP-1 and OCI-AML2 seem to be affected at lower concentrations, compared to HL60, OCI-
AML3 and HOXA9 (figure 5.2), but the results are not conclusive. No such trend is seen in the
annexin V apoptosis assay.
CXR9, intended to serve as a negative control, was also shown to cytotoxic to all the cell
lines examined, although the effect was weaker than that of HXR9. These results stand in
contradiction to previous studies, including Li et al [17], who have found CXR9 to work as
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intended with no impact on cell viability. A possible explanation of the effect of CXR9 is its
structural similarity with HXR9. Substitution of just one amino acid, even though it disrupts the
hexapeptide believed to be of great importance to it’s function [16, 36], may not be enough to
render CXR9 completely inactive, even though mutation analysis have shown that the particular
amino acid substituted in CXR9 is of vital importance to the YPWM motif [48]. CXR9 may
still be able to interfere with the interaction between HOX and PBX, albeit with a weaker effect
than that of HXR9. In addition, Shanmugam et al have shown that the amino acids flanking the
YPWM motif contribute to the interaction between HOX proteins and PBX [48]. The flanking
residues of CXR9 and HXR9 are identical and might thus contribute to the binding capacity of
CXR9.
In summary,we here show that HXR9 seems to be cytotoxic to AML cells but the effect
is less specific than expected as the negative control CXR9 also exhibit significant cytotoxic
effects.
6.3 Pro-differentiating effect of HXR9
6.3.1 Human cell lines
Results from the maturation panel suggest an increased maturation in samples exposed to
HXR9. The ratio of cells expressing the myeloid marker CD14 was increased and in OCI-
AML3 the increase is significant compared to CXR9 (figure 5.6b). The effect on THP-1 was
very weak, but it could be due to a lower peptide concentration of 5 uM instead of 10 uM. A
lower peptide concentration was chosen for this cell line due to their increased sensitivity to the
peptide and a higher concentration resulted in a reduced cell viability and trouble maintaining
exposure for seven days. The effect of HXR9 on HL60 is unclear. There was a trend towards
a rather dramatic increase in CD14+ population, but the measured variability was too high to
obtain any statistical significance. The study may be improved and better illustrate any pro-
maturating effect of HXR9 by testing an increased exposure time and possibly a higher peptide
concentration.
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DMSO was intended as a positive control for maturation. A first test run (data not shown)
showed a low cell viability in OCI-AML2 and OCI-AML3 after exposure to 1% DMSO, which
is the reason for lowering the concentration to 0.5%. This concentration, however, seems to be
too low to induce maturation and thus not ideal as a positive control. Should these experiments
be performed again, it would be preferable to use a higher concentration of DMSO even if it
would result in a reduced cell viability.
The results from the CFU experiment are inconclusive. There is a trend towards fewer
colonies in the samples treated with HXR9 (see figure 5.7), but it is not possible to distinguish if
this is due to the acute cytotoxic effect, probably resulting in a reduced number of cells surviving
the first day, or due to loss of proliferative capacity. If more replatings were performed and if
they would have shown a continuous reduction of colonies in the samples treated with HXR9
but not in the others, this would indicate that HXR9 has pro-differentiating, anti-proliferative
effect on the leukemic cells.
For OCI-AML3 there was no difference between samples exposed to CXR9 and negative
controls, but there were lesser colonies in the samples exposed to HXR9. For HL60 there was a
trend towards fewer colonies with CXR9 as well as HXR9, in accordance with cytotoxicity and
apoptosis assays. However, too few samples were available to perform a test of significance.
Interestingly, both OCI-AML3 and HL60 formed more colonies the second week. If it was
a true increase and not the result of a methodological error, it might be due to a selection of
cells with high proliferative capacity.
6.3.2 Murine cells
The results from the maturation assay on the liquid culture HOXA9 showed marked decrease in
expression of all the four maturation markers examined in the second experiment compared to
the first one, performed approximately one month apart (see figure 5.8). In addition, there was
a decrease in GFP-positve cells in the second experiment compared to the first, 60% compared
to 45%. A possible interpretation is that the cells have begun to lose the HOXA9-GFP construct
and possibly acquired additional mutations resulting in less mature, more leukemia-like cells.
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They may also have downregulated the expression of GFP but that would not explain the de-
crease of myeloid markers. According to Thorsteinsdottir et al.[10], it takes seven months for
mice injected with HOXA9 overexpressing cells to develop AML, which indicates that overex-
pression of HOXA9 alone is not enough to cause AML, but requires the acquisition of additional
mutations.
A delay of one month between experiments is far from optimal, especially when working
with a liquid culture that is more similar to primary bone marrow cells than the established cell
lines.
6.4 The efficiency of HXR9 in relation to the expression level of HOXA9
The working theory of this project was that HXR9 should induce apoptosis and possibly mat-
uration in AML cells with a high expression of HOXA9, due to the inhibition of the inter-
action between HOXA9 and PBX3. However, the results from all experiments presented in
this study, showed that both HXR9 and CXR9 are cytotoxic to and possibly pro-maturating for
HL60, which has a very low expression of HOXA9, according to the Western blot. Inhibition
of HOXA9 should have no or at least very little effect on these cells.
One of many possible explanations for the deviant results are that an unknown event oc-
curred affecting the peptides and rendering them unspecific. However, it seems improbable that
such an alteration would enhance the effect of CXR9, as one would instead expect a weakened
effect. Another explanation may be that something added at the same time as the peptides was
harmful to the cells. However, the peptides were dissolved in distilled water and diluted in the
same medium that the cells were cultured in and nothing else was intentionally added. As the
peptides were diluted at least 1:5,000 before coming in contact with the cells, any osmotic event
would too weak to be explain the phenomenon.
The most probable explanation, however, concerns the proposed mechanism of action of
the peptide. Opinions seems to differ about which HOX proteins contain a YPWM motif, the
sequence mimicked by HXR9. According to Morgan et al [35], the YPWM sequence is found
in HOX proteins of paralog groups 1–9, with references to others: Shanmugam et al [48],
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Chang et al [36], and Shen et al [49]. However, these authors all agree that YPWM is only
found in paralog groups 1–8. According to Shen et al HOX proteins of paralog groups 9–13
do not have a YPWM motif, but HOX proteins of groups 9–10 still bind to PBX1 [49]. If the
hexapeptide is not found in HOXA9, it would not be surprising that the effect of HXR9 is not
dependent on expression of HOXA9. Also, as the hexapeptide is present on all HOX proteins
of paralog groups 1–8/9, inhibition of the interaction with cofactor PBX3 would affect all these
other HOX proteins as well, possibly providing enough noise to erase any sign of correlation
between efficacy of HXR9 and expression level of HOXA9.
None of this explains the discrepancy between the results of Li et al and the results of this
study [17]. They tested the exact same peptides on the exact same cell lines (HL60 and THP-1)
but found that neither HXR9 nor CXR9 had any effect on HL60, and only HXR9 had any effect
on THP-1, in accordance with their expression of HOXA proteins. However there are a several
circumstances that can complicate a comparison:
1. The use of fetal calf/bovine serum in the culture medium. Serum is ill-defined and there
is a high variability between batches [50].
2. In their paper, Li et al. do not state exactly how the peptides were diluted and stored or
what cell concentrations they used [17].
3. Li et al. used another cell viability assay in their study [17].
6.5 Improvements and further investigations
Several improvements to the experiments performed are possible, such as to avoid long periods
of time between experiments and minor adjustments to concentrations of peptides. Also, to
exclude any disturbance caused by the fetal calf serum one could use a serum-free medium.
This would also eliminate problems with variability between batches of serum.
Concerning the lack of specificity of HXR9, one important aspect to consider is that HXR9
and the YPWM-motif do not seem to affect HOXA9 alone, but also many other HOX proteins
that collaborate with PBX3. Therefore, it would be of interest to explore the expression of
other HOX proteins and their relation to the efficacy of HXR9. It would also be interesting to
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examine whether changes to the amino acid sequence of HXR9 or CXR9 would have an impact.
For example, one could substitute both the tyrosine (Y) and the tryptophan (W) residues of the
YPWM-motif in CXR9, as these seem to be the most important ones for its binding to PBX3
[48], and clarify if that would render it less efficient and more suitable as a negative control.
Once specificity is obtained, the next step in the investigation of HXR9 as a possible treat-
ment would be to perform tests in vivo. A mouse xenograft model using OCI-AML3 cells is
under esablishment.
6.6 Conclusions
HXR9 exerts a cytotoxic and possibly pro-maturating effects on AML cells, but the effect may
be unspecific and independent of HOXA9 expression level. HOX-inhibition could still be a
potential future treatment option for AML but in the case of HXR9 more extensive studies
need to be performed concerning its mechanism of action, and a higher specificity needs to be
achieved.
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7 Populärvetenskaplig sammanfattning
HOX-inhibitorn HXR9:s verkan i akut myeloisk leukemi
I det här examensarbetet undersöktes huruvida substansen HXR9 skulle kunna vara en kandidat
för behandling av akut myeloisk leukemi.
Akut myeloisk leukemi (AML) är den vanligaste typen av akut leukemi — blodcancer — i
Sverige och som namnet antyder är förloppet hastigt. Dödligheten är hög, endast ca 20–30% av
patienterna lever 5 år efter diagnos. Prognosen är dock tydligt bättre för yngre patienter (<60
år).
Liksom alla typer av cancer uppstår AML då en frisk cell muterar, vilket innebär att det
uppstår förändringar i DNA. Mutationer som leder till cancer kännetecknas av att de gör att
celler får lättare att växa och dela sig och att de inte längre samarbetar med resten av kroppen.
Det är mycket intressant att veta exakt vilka mutationer som finns i cancerceller eftersom
mutationerna är tänkbara mål för läkemedelsbehandling. Nya cancerläkemedel som verkavia
sådana mutationer kan både vara mycket effektiva, eftersom det är just mutationerna som gör
cancercellerna så aggressiva, och dessutom kan de ge mindre biverkningar än t.ex. cellgifter,
eftersom ett dessa nya läkemedlel bara påverkar cancercellerna och inte de friska cellerna.
HXR9 är en substans som är designad att verka via mutationer som finns i just AML-celler.
I det här arbetet undersöktes vilken effekt substansen HXR9 har på AML-celler. Alla ex-
periment har skett på laboratorium och de undersökta cellerna kommer från etablerade cellinjer
som kan odlas där. För att kunna besvara frågeställningarna om HXR9:s effekt på AML-celler
har flera undersökningar gjorts:
• Kontroller för att bekräfta att cellerna har de egenskaper som förväntades.
• Celler utsattes för HXR9 och sedan undersöktes hur stor andel av cellerna som dött vid
olika koncentrationer samt huruvida cellerna dött kontrollerat eller okontrollerat. Okon-
trollerad celldöd är mer skadligt för omkringliggande celler och vävnad.
• Celler utsattes för låga koncentrationer av HXR9 under en längre tid och sedan undersök-
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tes cellerna för att se om de utvecklats till mer mogna celler. Detta är intressant då mogna
celler är mindre aggressiva och lättare att komma åt med redan etablerad leukemibehan-
dling.
Resultaten från experimenten visar att HXR9 är skadligt för AML-celler och gör att de dör kon-
trollerat. Vid experimenten användes en annan substans, CXR9, som negativ kontroll. Denna
är mycket lik HXR9 men en liten strukturell skillnad gör att den borde vara verkningslös. Ex-
perimenten visar dock att CXR9 också har förmåga att döda AML-celler, även om effekten är
svagare än för HXR9. Försöken som inriktades på att se om HXR9 kunde få AML-celler att
mogna visar att det finns en sådan trend, men den är svag och det går inte att utesluta att den
beror på slumpen.
Sammanfattningsvis visar arbetet att HXR9 kan orsaka celldöd och eventuellt ökad cell-
mognad vid AML, men effekten är inte så specifik som förväntat. Behandlingar som inriktas
på specifika mutationer är dock fortfarande högintressanta vid såväl AML som andra typer av
cancer.
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A Alamar Blue Assay
A.1 Equations
Equations provided by the data sheet for the Alamar Blue Cell Viability Reagent (Life Tech-
nologies).
(εOX)λ2Aλ1− (εOX)λ1
Aλ2(εRED)λ1A′λ2− (εRED)λ2A′λ1 (A.1)
(εOX)λ2(Aλ1−A′λ1)− (εOX)λ1(Aλ2−A′λ2)
(εOX)λ2(Aoλ1−A′λ1)− (εOX)λ1(Aoλ2−A′λ2) (A.2)
Table 4: Definition of variables for Alamar Blue equations.
VARIABLE DEFINITION
λ1 570 nm
λ2 600 nm
ε(OX)λ1
Molar extinction coefficient of Alamar Blue oxidized form (blue) for
wave-length λ1→ 80596
ε(OX)λ2
Molar extinction coefficient of Alamar Blue oxidized form (blue) for
wave-length λ2→ 117216
ε(RED)λ 1
Molar extinction coefficient of Alamar Blue reduced form (red) for
wave-length λ1→ 155677
ε(RED)λ2
Molar extinction coefficient of Alamar Blue reduced form (red) for
wave-length λ2→ 14652
A Absorbance of test well
A′
Absorbance of negative control well. This well should contain media
and Alamar Blue reagent, but no cells.
Ao
Absorbance of positive growth control well. This well should contain
cells, but no cytotoxic agent.
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Figure A.1: Test runs for optimization. The incubation time for the Alamar Blue reagent was
set to 4 hours for all cell lines and cell counts to 100,000 for HOXA9, 75,000 for HL60, OCI-
AML2 and OCI-AML3 and 50,000 for THP-1. Mean values and ± 2SD from one experiment
are shown.
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